来自“真实世界”的中国人 RA 中 TNF-α 抑制剂疗效的可预测性研究
从“真实世界”筛选预测中国人类风湿性关节炎患者对肿瘤坏死因子-α抑制剂治疗反应的蛋白并通过信号通路探讨其机制
研究概览
地位
条件
详细说明
研究类型
注册 (预期的)
阶段
- 第四阶段
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
- 自愿签署同意书
- 年龄在18-75岁之间
患者符合美国风湿病学会(ACR)
- 欧洲抗风湿病联盟(EULAR)2009年诊断标准(总分6分以上)
- 重症RA患者DAS28-CRP≥5.1
- 接受英夫利昔单抗加甲氨蝶呤的参与者将被邀请参加研究。
- 接受依那西普加甲氨蝶呤的参与者将被邀请参加研究。
- 将邀请接受阿达木单抗加甲氨蝶呤的参与者参加该研究。
排除标准:
- 患者有心血管、呼吸系统、肝脏、胃肠道、内分泌、血液学、神经病学或精神障碍的病史或疾病,研究者认为有这些病史或疾病的患者使用研究药物存在一定的风险,或者这些病史或疾病会干扰数据的解释
- 原位癌或存在癌变可能性的患者
- 基本或完全丧失行动能力,缺乏生活自理能力,如依赖轮椅或卧床不起。
- 实验检查显示下列任何一项:
谷草转氨酶或谷丙转氨酶>正常值上限的1.5倍 总胆红素>正常值上限的1.5倍 白细胞总数<2500个细胞/L 中性粒细胞绝对计数<1200个细胞/L 淋巴细胞计数<750 cells/L 血小板<100000/L
- 症状性单纯疱疹患者
- 潜伏结核信号(PPD+++ 或 T-SPOT>5)
- 乙型肝炎病毒 (HBV) 的阳性结果:
HBsAg + 或 HBeAg + 或 HBeAg + 或 HBcAb + 或 HBV DNA +
- 丙型肝炎病毒(HCV)+ 或 HCV RNA +
- HIV 感染或 HIV+
- 入组前1个月,从临床角度来看,患者有严重的病毒、细菌、真菌或寄生虫感染
- 怀孕、地点、备孕一年或有让伴侣怀孕的风险
- 患者接受过6个月的任何生物疗法,或参加过任何其他新药临床试验
- 药物过敏史
- 酗酒史
- 最近接种了活疫苗
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础_科学
- 分配:非随机
- 介入模型:平行线
- 屏蔽:没有任何
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:一个小组
允许使用英夫利昔单抗加甲氨蝶呤、来氟米特和非甾体抗炎药以及糖皮质激素,但不是必需的。
|
每位患者将以 10 毫克/周的剂量口服甲氨蝶呤,并且 MTX 剂量必须稳定至少 4 周。
其他名称:
英夫利昔单抗:静脉注射200mg,每次,0、2、6、14周,4次)
其他名称:
如果患者在入组前已收到 1 个月且 14 周内不会更改,则将允许 LEF。
其他名称:
如果患者在入组前已接受 1 个月且 14 周内不会更改,则允许使用非甾体抗炎药。
其他名称:
糖皮质激素(泼尼松小于 10mg/天,或等剂量的其他类似药物)如果患者在入组前已接受 1 个月,则允许使用,期间剂量不会改变。
其他名称:
|
实验性的:B组
允许使用依那西普加甲氨蝶呤、来氟米特和非甾体抗炎药以及糖皮质激素,但不是必需的。
|
每位患者将以 10 毫克/周的剂量口服甲氨蝶呤,并且 MTX 剂量必须稳定至少 4 周。
其他名称:
如果患者在入组前已收到 1 个月且 14 周内不会更改,则将允许 LEF。
其他名称:
如果患者在入组前已接受 1 个月且 14 周内不会更改,则允许使用非甾体抗炎药。
其他名称:
糖皮质激素(泼尼松小于 10mg/天,或等剂量的其他类似药物)如果患者在入组前已接受 1 个月,则允许使用,期间剂量不会改变。
其他名称:
依那西普:皮下注射,25mg/每周两次
其他名称:
|
实验性的:C组
允许使用阿达木单抗加甲氨蝶呤、来氟米特和非甾体抗炎药以及糖皮质激素,但不是必需的。
|
每位患者将以 10 毫克/周的剂量口服甲氨蝶呤,并且 MTX 剂量必须稳定至少 4 周。
其他名称:
如果患者在入组前已收到 1 个月且 14 周内不会更改,则将允许 LEF。
其他名称:
如果患者在入组前已接受 1 个月且 14 周内不会更改,则允许使用非甾体抗炎药。
其他名称:
糖皮质激素(泼尼松小于 10mg/天,或等剂量的其他类似药物)如果患者在入组前已接受 1 个月,则允许使用,期间剂量不会改变。
其他名称:
阿达木单抗:皮下注射,40mg/每周两次
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
将在 3 组患者中评估 EULAR(欧洲抗风湿病联盟)反应
大体时间:基线,第 14 周
|
EULAR(欧洲抗风湿病联盟)反应基于 DAS28-CRP 的变化。 根据 DAS28-CRP 从基线到第 14 周的变化定义以下良好、中等和无反应: >1.2 个单位为良好反应; 0.6-1.2 单位反应适中; ≤0.6个单位无反应。 DAS28-CRP 将在每次访问时在临床数据库中计算。 DAS28-CRP 评分评估的组成部分是:压痛/疼痛关节计数 (28);肿胀关节计数 (28)、hsCRP 和受试者一般健康 VAS 评估。 这种疗效测量将在基线和第 14 周进行。 |
基线,第 14 周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
将在3组患者中评估不同EULAR反应的TNF水平的变化。
大体时间:基线,第 14 周
|
TNF 水平评估是使用 ELISA 通过测试患者血清进行的直接测量。 该测量将在基线和第 14 周进行。 EULAR反应的分类和DAS28-CRP的计算基于上述主要结果测量。 |
基线,第 14 周
|
将在 3 组患者中评估具有不同 EULAR 反应的感兴趣蛋白的变化。
大体时间:基线,第 14 周
|
感兴趣的蛋白质将通过 iTRAQ(用于相对和绝对定量的同位素标签)进行筛选。 该测量将在基线和第 14 周时通过比较部分反应良好或无反应的患者进行。 筛选出的感兴趣蛋白将在3组所有患者中通过Western Blot进行验证。 EULAR反应的分类和DAS28-CRP的计算基于上述主要结果测量。 |
基线,第 14 周
|
将在 3 组患者中评估具有不同 EULAR 反应的 TNF 基因的 SNP(单核苷酸多态性)。
大体时间:第 14 周
|
TNF基因的SNP将通过PCR-RFLP(聚合酶链反应-限制性片段长度多态性)进行检测。 该测量将在第 14 周时在所有 3 组患者中进行。 EULAR反应的分类和DAS28-CRP的计算基于上述主要结果测量。 |
第 14 周
|
将在 3 组患者中评估具有不同 EULAR 反应的感兴趣蛋白基因的 SNP。
大体时间:第 14 周
|
目的蛋白基因的SNP将通过PCR-HRM(聚合酶链反应-高分辨率熔解)进行检测。 该测量将在第 14 周时在所有 3 组患者中进行。 在次要结果测量的上面筛选和验证感兴趣的蛋白质。 EULAR反应的分类和DAS28-CRP的计算基于上述主要结果测量。 |
第 14 周
|
合作者和调查者
赞助
出版物和有用的链接
一般刊物
- van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007 Jul;66(7):849-51. doi: 10.1136/ard.2007.069872.
- Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 Nov;68(11):1739-45. doi: 10.1136/ard.2008.092833. Epub 2008 Nov 19.
- Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdottir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22.
- Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J, Ye D, Xu S, Xu J, Zhang L, Pan F. Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013 May;23(3):489-95. doi: 10.1007/s10165-012-0699-5. Epub 2012 Jul 4.
- Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. doi: 10.1093/rheumatology/keh550. Epub 2005 Feb 3.
- Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, Kupper H, Becquemont L, Charron D, Mariette X. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008 Apr;67(4):478-84. doi: 10.1136/ard.2007.074104. Epub 2007 Aug 2.
- Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, Kuwana M. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014 Mar-Apr;32(2):211-7. Epub 2013 Dec 9.
- Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A; BRAGGSS. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ard.2007.084715. Epub 2008 Mar 28. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519.
- Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L, Bratt J. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003 Jun;62(6):526-9. doi: 10.1136/ard.62.6.526.
- Davila-Fajardo CL, Marquez A, Pascual-Salcedo D, Moreno Ramos MJ, Garcia-Portales R, Magro C, Alegre-Sancho JJ, Balsa A, Cabeza-Barrera J, Raya E, Martin J. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2014 Jan;24(1):1-5. doi: 10.1097/FPC.0000000000000013.
- Coulthard LR, Taylor JC, Eyre S; Biologics in Rheumatoid Arthritis Genetics and Genomics; Robinson JI, Wilson AG, Isaacs JD, Hyrich K, Emery P, Barton A, Barrett JH, Morgan AW, McDermott MF. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis. 2011 Jan;70(1):98-103. doi: 10.1136/ard.2010.133249. Epub 2010 Aug 30.
- Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS); Isaacs JD. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFkappaB signalling pathways. Ann Rheum Dis. 2010 Jul;69(7):1315-20. doi: 10.1136/ard.2009.117309. Epub 2010 May 6.
- Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; BRAGGSS; Barton A. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis. 2010 Jun;69(6):1029-35. doi: 10.1136/ard.2009.118406. Epub 2010 May 5. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519.
- Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedren S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL Jr, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010 Jul;62(7):1849-61. doi: 10.1002/art.27457.
- Krintel SB, Essioux L, Wool A, Johansen JS, Schreiber E, Zekharya T, Akiva P, Ostergaard M, Hetland ML. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. PLoS One. 2012;7(6):e38539. doi: 10.1371/journal.pone.0038539. Epub 2012 Jun 7.
- Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A, Kern M, Furie R, Dupuis J, Plenge RM, Coenen MJ, Behrens TW, Carulli JP, Gregersen PK. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med. 2008 Sep-Oct;14(9-10):575-81. doi: 10.2119/2008-00056.Liu.
- Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedren S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394. Epub 2013 Mar 28.
- Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, Lee AT, Huizinga TW, Allaart R, Barton A, Mariette X, Miceli CR, Criswell LA, Tak PP, de Vries N, Saevarsdottir S, Padyukov L, Bridges SL, van Schaardenburg DJ, Jansen TL, Dutmer EA, van de Laar MA, Barrera P, Radstake TR, van Riel PL, Scheffer H, Franke B, Brunner HG, Plenge RM, Gregersen PK, Guchelaar HJ, Coenen MJ. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis. 2013 Aug;72(8):1375-81. doi: 10.1136/annrheumdis-2012-202405. Epub 2012 Dec 11.
- Marquez A, Ferreiro-Iglesias A, Davila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E, Moreno-Ramos MJ, Garcia-Portales R, Navarro F, Moreira V, Magro C, Caliz R, Ferrer MA, Alegre-Sancho JJ, Joven B, Carreira P, Balsa A, Vasilopoulos Y, Sarafidou T, Cabeza-Barrera J, Narvaez J, Raya E, Canete JD, Fernandez-Nebro A, Ordonez Mdel C, de la Serna AR, Magallares B, Gomez-Reino JJ, Gonzalez A, Martin J. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther. 2014 Mar 11;16(2):R66. doi: 10.1186/ar4504.
- Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One. 2010 Jun 25;5(6):e11310. doi: 10.1371/journal.pone.0011310.
- Pachot A, Arnaud B, Marrote H, Cazalis MA, Diasparra J, Gouraud A, Mougin B, Miossec P. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol. 2007 Nov;34(11):2158-61. Epub 2007 Sep 15.
- Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford). 2008 Jun;47(6):780-8. doi: 10.1093/rheumatology/ken083. Epub 2008 Apr 3.
- Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, Marsal S. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One. 2009 Oct 22;4(10):e7556. doi: 10.1371/journal.pone.0007556.
- Stuhlmuller B, Haupl T, Hernandez MM, Grutzkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2010 Mar;87(3):311-21. doi: 10.1038/clpt.2009.244. Epub 2009 Dec 23.
- Meugnier E, Coury F, Tebib J, Ferraro-Peyret C, Rome S, Bienvenu J, Vidal H, Sibilia J, Fabien N. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. Physiol Genomics. 2011 Apr 12;43(7):365-71. doi: 10.1152/physiolgenomics.00127.2010. Epub 2011 Jan 25.
- Wright HL, Thomas HB, Moots RJ, Edwards SW. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford). 2015 Jan;54(1):188-93. doi: 10.1093/rheumatology/keu299. Epub 2014 Aug 13.
- Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol. 2008 Aug;153(2):188-95. doi: 10.1111/j.1365-2249.2008.03691.x. Epub 2008 Jun 18.
- Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R76. doi: 10.1186/ar2706. Epub 2009 May 21.
- Trocme C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, Miossec P, Tebib J, Berger F, Nissen MJ, Juvin R, Morel F, Gaudin P. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis. 2009 Aug;68(8):1328-33. doi: 10.1136/ard.2008.093153. Epub 2008 Jul 29.
- Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 2010;12(6):R211. doi: 10.1186/ar3188. Epub 2010 Nov 17.
- Sakthiswary R, Shaharir SS, Mohd Said MS, Asrul AW, Shahril NS. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Int J Rheum Dis. 2014 Nov;17(8):872-7. doi: 10.1111/1756-185X.12443. Epub 2014 Oct 7.
- Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Ronnelid J. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008 Jan;58(1):36-45. doi: 10.1002/art.23188.
- Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol. 2007 Aug;26(8):1335-8. doi: 10.1007/s10067-006-0520-y. Epub 2007 Feb 7.
- Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007 Dec;66(12):1675-8. doi: 10.1136/ard.2007.071910. Epub 2007 Jul 31.
- Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb;62(2):392-401. doi: 10.1002/art.27226.
- Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.
- Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, McInnes IB, Raza K, Young SP. Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013 Jun;65(6):1448-56. doi: 10.1002/art.37921.
- Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther. 2011 Jul 30;13(4):R126. doi: 10.1186/ar3431.
- Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM. Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol. 2013 Oct;174(1):18-26. doi: 10.1111/cei.12161.
- Tanaka Y, Matsumoto I, Iwanami K, Inoue A, Umeda N, Tanaka Y, Sugihara M, Hayashi T, Ito S, Sumida T. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012 Jan-Feb;30(1):99-102. Epub 2012 Mar 6.
- Daien CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014:386148. doi: 10.1155/2014/386148. Epub 2014 Jan 12.
- Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gulfe A, Saxne T, Geborek P. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken). 2014 Feb;66(2):173-9. doi: 10.1002/acr.22107.
- Xie X, Zhang D, Chen JW, Tian J, Ling GH, Li F. Pharmacogenomics of biological treatment in rheumatoid arthritis. Expert Opin Biol Ther. 2014 Feb;14(2):157-64. doi: 10.1517/14712598.2014.859672. Epub 2013 Dec 3.
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- XYEYY-GZ81571599-20160118-1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.